Literature DB >> 18021714

[Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present].

Anne-Marie Laberge1.   

Abstract

The prevalence and distribution of genetic diseases in the province of Quebec has been influenced by its population history. The current French Canadian population stems from 8,500 pioneers who left France for Nouvelle-France between 1608 and 1759. After the English conquest of Nouvelle-France in 1759, the French Canadian population remained mostly genetically isolated, for linguistic, cultural, and religious reasons. The migration of a small number of French individuals to Nouvelle-France created a founder effect. Subsequent migrations inland have created smaller regional founder effects. The limited size of the population favoured genetic drift, and the social context encouraged endogamy, i.e. unions between French Canadians with little admixture with English and other immigrants. Founder effects, genetic drift, and endogamy have all played a role in the current prevalence and distribution of genetic diseases now found in Quebec. The prevalence and distribution of genetic diseases in Quebec need to be taken into account in clinical practice. When clinicians are knowledgeable about the genetic diseases prevalent in the population they treat, they know to consider these diseases in differential diagnoses when appropriate and prioritize investigations accordingly. When developing a new diagnostic test for a genetic disease, the prevalence of the disease and the nature of the mutations found in the target population need to be taken into account. The performance of the test will depend on how well it accounts for the particularities of the disease in that population. In other words, how well does it detect the mutations found in that population? Interpretation of individual genetic test results will also depend on how well the test is expected to perform in the individual's population.

Entities:  

Mesh:

Year:  2007        PMID: 18021714     DOI: 10.1051/medsci/20072311997

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  5 in total

1.  Geographical variation of Crohn's disease residual incidence in the Province of Quebec, Canada.

Authors:  Pascal Michel; Laurie St-Onge; Anne-Marie Lowe; Michel Bigras-Poulin; Paul Brassard
Journal:  Int J Health Geogr       Date:  2010-05-12       Impact factor: 3.918

2.  Pathogenic variants carrier screening in New Brunswick: Acadians reveal high carrier frequency for multiple genetic disorders.

Authors:  Philippe Pierre Robichaud; Eric P Allain; Sarah Belbraouet; Claude Bhérer; Jean Mamelona; Jason Harquail; Stéphanie Crapoulet; Nicolas Crapoulet; Mathieu Bélanger; Mouna Ben Amor
Journal:  BMC Med Genomics       Date:  2022-04-29       Impact factor: 3.622

3.  The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Authors:  Rodica Gilca; Geneviève Deceuninck; Brigitte Lefebvre; Raymond Tsang; Rachid Amini; Vladimir Gilca; Monique Douville-Fradet; France Markowski; Philippe De Wals
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

4.  Whole-exome sequencing reveals a rapid change in the frequency of rare functional variants in a founding population of humans.

Authors:  Ferran Casals; Alan Hodgkinson; Julie Hussin; Youssef Idaghdour; Vanessa Bruat; Thibault de Maillard; Jean-Christophe Grenier; Jean-Cristophe Grenier; Elias Gbeha; Fadi F Hamdan; Simon Girard; Jean-François Spinella; Mathieu Larivière; Virginie Saillour; Jasmine Healy; Isabel Fernández; Daniel Sinnett; Jacques L Michaud; Guy A Rouleau; Elie Haddad; Françoise Le Deist; Philip Awadalla
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

5.  Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.

Authors:  Anick Bérard; Shannon Strom; Jin-Ping Zhao; Shashi Kori; Detlef Albrecht
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.